Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Public Health and Health Systems Impacts of SARS-CoV-2 Variants of Concern: A Rapid Scoping Review

J Curran, View ORCID ProfileJ Dol, L Boulos, M Somerville, H McCulloch
doi: https://doi.org/10.1101/2021.05.20.21257517
J Curran
1Dalhousie University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jacurran{at}dal.ca
J Dol
1Dalhousie University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J Dol
L Boulos
2Maritime SPOR Support Unit
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Somerville
1Dalhousie University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H McCulloch
3IWK Health Centre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background As of April 2021, three SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351 and P.1) have been detected in over 132 countries. Increased transmissibility of VOC has implications for public health measures and health system arrangements. This rapid scoping review aims to provide a synthesis of current evidence related to public health measures and health system arrangements associated with VOC.

Methods Rapid scoping review. Seven databases were searched up to April 7, 2021 for terms related to VOC, transmission, public health and health systems. A grey literature search was conducted up to April 14, 2021. Title, abstracts and full text were screened independently by two reviewers. Data were double extracted using a standardized form. Studies were included if they reported on at least one of the VOC and public health or health system outcomes.

Results Of the 2487 articles and 59 grey literature sources retrieved, 37 studies and 21 guidance documents were included. Included studies used a wide range of designs and methods. Most of the studies and guidance documents reported on B.1.1.7, and 18 studies and 4 reports provided data for consideration in relation to public health measures. Public health measures, including lockdowns, physical distancing, testing and contact tracing, were identified as critical adjuncts to a comprehensive vaccination campaign. No studies reported on handwashing or masking procedures related to VOC. For health system arrangements, 17 studies were identified. Some studies found an increase in hospitalization due to B.1.1.7 but no difference in length of stay or ICU admission. Six studies found an increased risk of death ranging from 15-67% with B.1.1.7 compared non-B.1.1.7, but three studies reported no change. One study reported on the effectiveness of personal protective equipment in reducing VOC transmission in the hospital. No studies reported on screening staff and visitors, adjusting service provisions, or adjusting patient accommodations and shared spaces, which is a significant gap in the literature. Guidance documents did not tend to cite any evidence and were thus assumed to be based on expert opinion.

Conclusion While the findings should be interpreted with caution as most of the sources identified were preprints, findings suggest a combination of non-pharmaceutical interventions (e.g., masking, physical distancing, lockdowns, testing) should be employed alongside a vaccine strategy to improve population and health system outcomes. While the findings are mixed on the impact of VOC on health system arrangements, the evidence is trending towards increased hospitalization and death.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work is support by: The SPOR Evidence Alliance (SPOR EA), which is supported by the Canadian Institutes of Health Research (CIHR) under the Strategy for Patient-Oriented Research (SPOR) initiative, and the COVID-19 Evidence Network to support Decision-making (COVID-END), which is supported by the Canadian Institutes of Health Research (CIHR) through the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding opportunity.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

No ethical approval was required as it is a review.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data is available upon reasonable request from corresponding author.

  • Definitions & Abbreviations

    ABM
    Agent-based Model
    AGREE II
    Appraisal of Guidelines Research and Evaluation
    aIRR
    adjusted incidence rate ratios
    B.1.1.7
    variant of concern originating in the United Kingdom, also known as VUI 202012/01 and VOC 202012/01
    B.1.351
    variant of concern originating in South Africa, also known as 20H/501Y.V2
    BMI
    body mass index
    CanCOGen
    Canadian COVID Genomics Network
    CENTRAL
    Central Register of Controlled Trials
    CFR
    Case Fatality Rates
    CI
    confidence interval
    CIDRAP
    Center for Infectious Disease Research and Policy
    Ct
    cycle threshold, provides a relative measure of viral quantity
    COG-UK
    COVID-19 Genomics UK
    CDSR
    Cochrane Database of Systematic Reviews
    dQALY
    discounted quality-adjusted life years
    E484K
    escape mutation in the SARS-CoV-2 virus, present in B.1.1.7
    ECDC
    European Centres for Disease Control
    FDA
    Food and Drug Administration
    HCW
    healthcare workers
    HR
    Hazard Ratio
    HVAC
    heating, ventilation, and air conditioning
    ICU
    Intensive Care Unit
    IQR
    interquartile range
    IR
    incidence rate
    LOS
    length of stay
    mRNA
    messenger ribonucleic acid
    NGS
    next generation sequencing
    NOS
    Newcastle-Ottawa scale
    NPI
    Non-Pharmaceutical Interventions
    NRW
    North-Rhine Westphalia
    OR
    odds ratio
    P.1
    variant of concern originating in Brazil, also known as B.1.28.1
    PCR
    polymerase chain reaction, method for DNA replication and genome sequencing
    PHU
    Public Health Unit
    PPE
    personal protective equipment
    PR
    prevalence ratio
    R
    reproduction
    R0
    basic reproduction number, expected number of cases generated by one case in a population when everyone is susceptible to infection
    Rt
    effective reproduction number
    RR
    risk ratio
    RT-LAMP
    reverse transcription loop-mediated and transcription-mediated amplification isothermal amplification
    RTD
    Rapid Antigen Test
    SA
    South Africa
    SAPSII
    severity score at admission
    SIDARTHE
    a type of model
    SGTF
    spike OR S gene target failure, correlates with the increase of confirmed, sequenced variants
    SGTL
    spike gene late detection
    SD
    standard deviation
    UK
    United Kingdom
    US
    United States
    VE
    vaccine efficiency
    VOC
    variant of concern
    WHO
    World Health Organization
    WGS
    whole genome sequencing
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted May 22, 2021.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Public Health and Health Systems Impacts of SARS-CoV-2 Variants of Concern: A Rapid Scoping Review
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Public Health and Health Systems Impacts of SARS-CoV-2 Variants of Concern: A Rapid Scoping Review
    J Curran, J Dol, L Boulos, M Somerville, H McCulloch
    medRxiv 2021.05.20.21257517; doi: https://doi.org/10.1101/2021.05.20.21257517
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Public Health and Health Systems Impacts of SARS-CoV-2 Variants of Concern: A Rapid Scoping Review
    J Curran, J Dol, L Boulos, M Somerville, H McCulloch
    medRxiv 2021.05.20.21257517; doi: https://doi.org/10.1101/2021.05.20.21257517

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Public and Global Health
    Subject Areas
    All Articles
    • Addiction Medicine (349)
    • Allergy and Immunology (668)
    • Allergy and Immunology (668)
    • Anesthesia (181)
    • Cardiovascular Medicine (2648)
    • Dentistry and Oral Medicine (316)
    • Dermatology (223)
    • Emergency Medicine (399)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
    • Epidemiology (12228)
    • Forensic Medicine (10)
    • Gastroenterology (759)
    • Genetic and Genomic Medicine (4103)
    • Geriatric Medicine (387)
    • Health Economics (680)
    • Health Informatics (2657)
    • Health Policy (1005)
    • Health Systems and Quality Improvement (985)
    • Hematology (363)
    • HIV/AIDS (851)
    • Infectious Diseases (except HIV/AIDS) (13695)
    • Intensive Care and Critical Care Medicine (797)
    • Medical Education (399)
    • Medical Ethics (109)
    • Nephrology (436)
    • Neurology (3882)
    • Nursing (209)
    • Nutrition (577)
    • Obstetrics and Gynecology (739)
    • Occupational and Environmental Health (695)
    • Oncology (2030)
    • Ophthalmology (585)
    • Orthopedics (240)
    • Otolaryngology (306)
    • Pain Medicine (250)
    • Palliative Medicine (75)
    • Pathology (473)
    • Pediatrics (1115)
    • Pharmacology and Therapeutics (466)
    • Primary Care Research (452)
    • Psychiatry and Clinical Psychology (3432)
    • Public and Global Health (6527)
    • Radiology and Imaging (1403)
    • Rehabilitation Medicine and Physical Therapy (814)
    • Respiratory Medicine (871)
    • Rheumatology (409)
    • Sexual and Reproductive Health (410)
    • Sports Medicine (342)
    • Surgery (448)
    • Toxicology (53)
    • Transplantation (185)
    • Urology (165)